Literature DB >> 11343123

ICOS is essential for effective T-helper-cell responses.

A Tafuri1, A Shahinian, F Bladt, S K Yoshinaga, M Jordana, A Wakeham, L M Boucher, D Bouchard, V S Chan, G Duncan, B Odermatt, A Ho, A Itie, T Horan, J S Whoriskey, T Pawson, J M Penninger, P S Ohashi, T W Mak.   

Abstract

The outcome of T-cell responses after T-cell encounter with specific antigens is modulated by co-stimulatory signals, which are required for both lymphocyte activation and development of adaptive immunity. ICOS, an inducible co-stimulator with homology to CD28, is expressed on activated, but not resting T cells, and shows T-cell co-stimulatory function in vitro. ICOS binds specifically to its counter-receptor B7RP-1 (refs 5,6,7), but not to B7-1 or B7-2. Here we provide in vivo genetic evidence that ICOS delivers a co-stimulatory signal that is essential both for efficient interaction between T and B cells and for normal antibody responses to T-cell-dependent antigens. To determine the physiological function of ICOS, we generated and characterized gene-targeted ICOS-deficient mice. In vivo, a lack of ICOS results in severely deficient T-cell-dependent B-cell responses. Germinal centre formation is impaired and immunoglobulin class switching, including production of allergy-mediating IgE, is defective. ICOS-deficient T cells primed in in vivo and restimulated in vitro with specific antigen produce only low levels of interleukin-4, but remain fully competent to produce interferon-gamma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11343123     DOI: 10.1038/35051113

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  181 in total

Review 1.  Chemokines: the times they are a-changin'.

Authors:  G Márquez; C Martínez-A
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 2.  Role of adhesion molecules in activation signaling in T lymphocytes.

Authors:  M L Dustin
Journal:  J Clin Immunol       Date:  2001-07       Impact factor: 8.317

Review 3.  Naive and memory B cells in T-cell-dependent and T-independent responses.

Authors:  R H Zubler
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 4.  Activation and inhibition of lymphocytes by costimulation.

Authors:  Kenneth A Frauwirth; Craig B Thompson
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

5.  ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6.

Authors:  Youn Soo Choi; Robin Kageyama; Danelle Eto; Tania C Escobar; Robert J Johnston; Laurel Monticelli; Christopher Lao; Shane Crotty
Journal:  Immunity       Date:  2011-06-24       Impact factor: 31.745

Review 6.  Immunology of B7-H1 and its roles in human diseases.

Authors:  Hideto Tamura; Kiyoyuki Ogata; Haidong Dong; Lieping Chen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 7.  CTLA4 gene and autoimmune endocrinopathies: a new marker?

Authors:  F Pociot
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

8.  The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity.

Authors:  Hiroshi Harada; Alan D Salama; Masayuki Sho; Atsushi Izawa; Sigrid E Sandner; Toshiro Ito; Hisaya Akiba; Hideo Yagita; Arlene H Sharpe; Gordon J Freeman; Mohamed H Sayegh
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

9.  Activation of diverse repertoires of autoreactive T cells enhances the loss of anti-dsDNA B cell tolerance.

Authors:  Brian W Busser; Brigette S Adair; Jan Erikson; Terri M Laufer
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

10.  The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas.

Authors:  Luka de Vos; Ingela Grünwald; Emma Grace Bawden; Jörn Dietrich; Kathrin Scheckenbach; Constanze Wiek; Romina Zarbl; Friedrich Bootz; Jennifer Landsberg; Dimo Dietrich
Journal:  Epigenetics       Date:  2020-04-21       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.